A Retrospective Observational Study on Treatment Outcomes Following Switching to Anti-IL-5 Therapy in EGPA

Retrospective Observational Study on Treatment Efficacy Following Switching from Neutralizing Antibodies to Receptor Antibodies in EGPA - Observational Study on Switching Antibody Therapies in EGPA

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000059198

Enrollment

Registered

2025-11-01

Start date

2025-04-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

eosinophilic granulomatosis with polyangiitis: EGPA

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients undergoing anti-IL-5 antibody therapy for EGPA. Patients who provided consent.

Exclusion criteria

Exclusion criteria: Patients who did not provide consent.

Design outcomes

Primary

Measure	Time frame
Asthma Symptom Score (ACT), Lung Function, Peripheral Eosinophil Count	—

Countries

Japan

Contacts

Public ContactTakehito KOBAYASHI

Saitama Medical University Hospital / Saitama Prefectural Cardiovascular and Respiratory Center General Internal Medicine, Respiratory Medicine, Emergency Medicine / General Internal Medicine

kobayashi.takehito@1972.saitama-med.ac.jp048-536-9900

Outcome results